Immunocore Holdings (IMCR) Net Cash Flow Growth (1y) (2022 - 2026)

Immunocore Holdings (IMCR) Net Cash Flow Growth (1y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -88.82%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 301.06%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 453.08%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -125.22%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Immunocore Holdings 1.72 Bn 878.48 Mn 106.24 Mn -170.15%

Historic Data

Download Data
DateValue
Mar 31, 2026 -170.15%
Dec 31, 2025 57.61%
Sep 30, 2025 -87.01%
Jun 30, 2025 99.76%
Mar 31, 2025 -96.75%
Dec 31, 2024 -461.17%
Sep 30, 2024 1.20%
Mar 31, 2024 2,758.78%
Dec 31, 2023 -302.65%
Sep 30, 2023 -86.34%
Dec 31, 2022 114.50%